PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1997/50/2.


Piotr Kaczmarek, Eugeniusz Miękoś
Klinika Urologii Instytutu Chirurgii WAM w Łodzi
Kierownik Kliniki: prof. dr hab. med. E. Miękoś


bladder bladder carcinoma BCG-therapy


Objective. The authors present the results of two years observation of 65 patients with
superficial bladder tumours.
Material and method. After electroresection of tumours 22 (34%) patients were given
instillations BCG, 26 (40%) patients were given instillations Adriblastin, but 19 (22%)
patients were not given any medicine (the patients didn't come for the next part of
Results. During the further observation of the patients, it come out that in the grup I ?
BCG there was no recurrent tumour with 13 (59%) patients, in the grup II ? ADR there
was no recurrent tumour with 11 (42%) patients, Comparing to only 4 (21%) patients in the III grup.
Conclusions. BCG intravesical instillations after transurethral electroresection were
the most effective in the superficial bladder tumours treatment.


  1. [1] Bretton, P. R., Hen, A. W., Kimmel, M.: The response of patients with supper-
  2. ficial bladder cancer to a second of intrauesical BCG. J. Urol., 1990 Apr., 143 (4),
  3. 710-712.
  4. [2] Catalowa, W. I., Ratliff, T. L.: Bacillus Calmette-Guerin and superficial blad-
  5. der cancer. Clinical experience and mechanism of action. Surg. Ann., 1990, 22,
  6. 363-378.
  7. [3] D'Ancona, C. A., Netto Junior, N. R., Claro, J. A.: Oral or intravesical
  8. bacillus Calmette-Guerin immunoprophylaxsis in bladder carcinoma. J. Urol., 1991
  9. Mar., 145 (3), 498-501.
  10. [4] Franssen, M. P. H., de Mulder, P. H. M., Doesburg, W. H.: Combination
  11. therapy with recombinat interferon - alpha and - gamma in advanced renal cell
  12. carcinoma - a phase I -II study. Immunotherapy of urological tumors, Chur-
  13. chill Livingstone, 1990,163-171.
  14. [5] Graziano, D. A., Jacobs, D., Lozano, R. G., Buck, R. O.: A case of granulo-
  15. matous hepatitis after intravesical Bacillus Calmette - Guerin administration. }.
  16. Urol., 1991,146(4), 1118-1119.
  17. [6] Khanna, O. R, Son, D. L., Macer, H., Read, )., Nugent, D.: Multicenter
  18. study of superficial bladder cancer treated with intravesical bacillus Calmette-Gu-
  19. erin or adriamycin. Urology, 1990, 35(2), 101-108.
  20. [7] Lamm, D. L.: Adriamycin vs. BCG in superficial bladder cancer. Interface 11,1989.
  21. [8] Lamm, D. L., De Haven, J. I., Shriver, J.: Prospectwe randomized Compari-
  22. son of intravesical with Percutaneous bacillus Calmette - Guerinuersus intrauesical
  23. BCG in superficial bladder cancer. J. Urol., 1991,145(4), 738-740.
  24. [9] Martinez Pineiro, J. A., Martinez Pineiro Jr., ]., Garcia Motres, J.: BCG
  25. vs. dozorubicin vs. thiotepa instilation for primary superficial bladder cancer. Immu-
  26. notherapy of Urological Tumours, Society Internationale D'Urologie, 1990,59-
  27. 68.
  28. [10] Rubben, H., Weissbach, L., Knebel, L.: Adjuyant systemic chemotherapy after
  29. complete transurethral resection of superficially invasive bladder carcinoma.
  30. (T 1 G 3-4 andT2G 2-4). Urol. Int., 1990, 45(2), 78-83.
  31. [11] Rubben, H., Graf Doberstein, C.: Prospectwe rondomized study of adjuyant
  32. therapy after complete resection of superficial bladder cancer., mitomycin C vs. BCG
  33. Connaught vs. TUR alone. Immunotherapy of urological tumors, Society In-
  34. ter-nationale D'Urologie, 1990, 27-36.
  35. [12] Steg, A., Adjiman, S., Debre, B.: BCG therapy in superficial bladder tumours
  36. complication and precautions. Eur. Urol., 1992, 21 (supp 2), 35-40.
  37. [13] Yamamoto, T., Hagiwara, M., Nakazano, M.: Intravesical bacillus Calmette -
  38. Guerin in the treatment of superficial bladder cancer. Prospectw randomized study for
  39. prophilactic effect. Nippon Hinyokika Gakkai Zsshi, 1990, 81(7), 997-1001.
  40. [14] Zieliński, J.: Onkologia urologiczna, PZWL, 1986.